Perlegen Sciences Introduces Breast Cancer Risk Stratification Test
Perlegen Sciences, which develops genetic tests that correlate genetic variation to disease risk and drug response, announced today that its BREVAGen breast cancer risk stratification test is now clinically available in select US markets.
Read More